Concordance of Programmed Death-Ligand 1 Expression between SP142 and 22C3/SP263 Assays in Triple-Negative Breast Cancer

PURPOSE: Triple-negative breast cancer (TNBC) represents a major clinical challenge due to its aggressive and metastatic behavior and the lack of available targeted therapies. Therefore, therapeutic strategies are needed to improve TNBC patient management. Recently, atezolizumab and nab-paclitaxel c...

Descripción completa

Detalles Bibliográficos
Autores principales: Lee, Seung Eun, Park, Ha Young, Lim, So Dug, Han, Hye Seung, Yoo, Young Bum, Kim, Wan Seop
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Korean Breast Cancer Society 2020
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7311361/
https://www.ncbi.nlm.nih.gov/pubmed/32595992
http://dx.doi.org/10.4048/jbc.2020.23.e37

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7311361/
https://www.ncbi.nlm.nih.gov/pubmed/32595992
http://dx.doi.org/10.4048/jbc.2020.23.e37

Ejemplares similares